Litcius/Paper detail

Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches

Jing Zhao, Wanting Xu, Fei Zhou, Xiangyu Zhang, Mo Zhou, Da Miao, Yu Lan, Yongchang Zhang, Junqiang Fan, Caicun Zhou, Wen Li, Tony Mok, Xiuning Le, Molly Li, Yang Xia

2025Nature Reviews Clinical Oncology19 citationsDOI

Topics & Concepts

MedicineErlotinibGefitinibAcquired resistanceAfatinibDrug resistanceEGFR inhibitorsClinical trialTherapeutic approachTyrosine kinasePersonalized medicineCancer researchLung cancerTargeted therapyBioinformaticsOsimertinibResistance (ecology)Erlotinib HydrochloridePrecision medicineCombination therapyEpidermal growth factor receptorTyrosine-kinase inhibitorComputational biologyCancerDruggabilityLung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersRadiomics and Machine Learning in Medical Imaging
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches | Litcius